Localisation of X linked recessive idiopathic hypoparathyroidism to a 1.5 Mb region on Xq26-q27

D Trump, P H Dixon, S Mumm, C Woodying, K E Davies, D Schlessinger, M P Whyte, R V Thakker

Abstract

X linked recessive idiopathic hypoparathyroidism (HPT) has been observed in two kindreds from Missouri, USA. Affected subjects, who are males, suffer from infantile onset of epilepsy and hypocalcaemia, which appears to be the result of an isolated congenital defect of parathyroid gland development; females are not affected and are normocalcaemic. The gene causing HPT has been previously mapped to a 7 cM interval, flanked centromerically by F9 and telomerically by DXS98, in Xq26-q27, and an analysis of mitochondrial DNA has established a common ancestry for these two kindreds. In order to define further the map location of HPT and thereby facilitate its isolation, we have undertaken linkage studies using polymorphic loci whose order has been established as Xcen - DXS1001 - DXS294 - DXS102 - F9 - DXS1232 - DXS984 - CDRI - DXS105 - DXS1205 - DXS1227 - DXS98 - DXS52 - Xqter, within this region. Our results established linkage (lod score >3) between HPT and eight of these 12 loci and indicated that the most likely location of HPT was within a 1.5 Mb interval flanked centromerically by F9 and telomerically by DXS984. Thus, the results of this study have helped to refine the map location of HPT, and this will facilitate the identification of this putative developmental gene and its role in the embryological formation of the parathyroids. (J Med Genet 1998;35:905–909)

Keywords: parathyroid gland development; hypocalcaemia

Hypoparathyroidism is an endocrine disorder in which hypocalcaemia and hyperphosphataemia are the results of a deficiency of parathyroid hormone (PTH) secretion. There are a variety of causes of hypoparathyroidism and the disorder may occur after trauma to the parathyroids during neck surgery, or as part of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome, or as a congenital defect as in DiGeorge syndrome. In addition, hypoparathyroidism may develop as a solitary endocrinopathy and this form has been called isolated or idiopathic hypoparathyroidism. Familial occurrences of idiopathic hypoparathyroidism have been reported and autosomal dominant, autosomal recessive, and X linked recessive inheritances have been established. Some of the autosomal forms of hypoparathyroidism have been shown to be the result of either mutations of the PTH gene, which is located on chromosome 11p15, or of the calcium sensing receptor gene, which is located on chromosome 3q13.3-3q21. The gene causing the X linked recessive form, which is likely to involve a putative, developmental gene and has been mapped to Xq26-q27, remains to be isolated.

X linked recessive idiopathic hypoparathyroidism (HPT) has been reported to occur in two multigeneration kindreds, family P/60 and W/81 (fig 1), from Missouri, USA. Affected subjects, who are males, suffered from neonatal or infantile onset of hypocalcaemic seizures that were invariably fatal if the hypocalcaemia remained uncorrected. Further investigations of these male patients showed undetectable circulating immunoreactive PTH concentrations and a normal renal response to bovine PTH extract. In addition, necropsy of an affected teenage boy from family P/60 indicated that the deficiency in PTH was the result of parathyroid gland agenesis. Clinical immuno-deficiency, a notable feature of DiGeorge syndrome, has not been observed in any of the affected males. Unaffected relatives including carrier females, who were the mothers or grandmothers of affected boys, had no history of epilepsy and were normocalcaemic.

The two HPT kindreds, which are both from eastern Missouri, appeared to be unrelated, as a common ancestor was not identified despite extensive genealogy dating back to the mid-1800s. However, an analysis of mitochondrial DNA, which is maternally inherited, identified that the D loop sequences in the affected males from both kindreds were identical, thereby establishing their common ancestry. Linkage studies have mapped the HPT gene to a 7 cM interval flanked centromerically by factor IX (F9) and telomerically by DXS98 in Xq26-Xq27. We have pursued additional linkage studies in these two HPT families using 12 polymorphic markers, with the aim of further defining the chromosomal segment containing HPT, and thereby facilitating its identification by positional cloning.

Materials and methods

FAMILIES

Two kindreds from Missouri, in whom idiopathic hypoparathyroidism had been inherited...
**Family W/81**

- **I**
  - **II**
  - **III**
  - **IV**
  - **V**

**Family P/60**

- **I**
  - **II**
  - **III**
  - **IV**
  - **V**

---

**Figure 1** Pedigrees from families W/81 (A) and P/60 (B), segregating for X-linked recessive idiopathic hypoparathyroidism and the 12 polymorphic loci (Xcen to DXS984) in DXS102 - Xqter, whose respective alleles are indicated. Filled in symbols are affected subjects, symbols with a dot in the middle are carriers. In some females, the inheritance of paternal and maternal alleles can be ascertained, and in these the paternal X chromosome haplotype is shown on the left. Deduced genotypes are shown in brackets. Recombinants between HPT and each locus, observed in the affected males, carrier females, and unaffected males, are indicated by an asterisk. Thus, in family W/81, III.6, II.13, IV.1, IV.7, IV.10, IV.11, V.1, and V.8, and in family P/60, W.10, show recombinants between HPT and the X-linked polymorphic loci; these recombinants located HPT in the interval telomeric to DXS984.
in an X linked recessive manner in five or more generations and in whom linkage between the disease and the Xq26-q27 locus DXS989 had been established, were investigated. The family reported by Pedersen in 1960 was designated P/60 and that reported by Whyte and Weldon in 1981 was designated family W/81 (fig 1). Venous blood was obtained, after informed consent, from 61 family members (six affected males, 11 carrier females, and 44 unaffected (16 males, 28 females) subjects).

**GENETIC MARKERS**

Leucocyte DNA was prepared from venous blood samples and used to detect restriction fragment length polymorphisms (RFLPs) and polymorphisms in microsatellite tandem repeats, as previously described. The six loci DXS294, F9, CDR, DXS105, DXS98, and DXS52 defined RFLPs and the six loci DXS1001, DXS102, DXS1232, DXS984, DXS1205, and DXS1227 defined microsatellite polymorphisms (GenBank).

**LINKAGE ANALYSIS**

The data from the present and previously reported study of both the families, which were established by mitochondrial DNA analysis to be related, were pooled for linkage studies. Conventional two point lod scores and multipoint location scores were calculated using the LINKAGE computer programs, version 5.1, on a 64 megabyte RAM Sun 4-90 computer running Sun OS4.1.1 as described. The fixed order of loci and the genetic distances between the respective intervals required for multilocus analysis were deduced from published genetic maps, and the order of loci was taken as Xcen - DXS1001 - DXS294 - DXS102 - F9 - DXS1232 - DXS984 - CDR1 - DXS105 - DXS1205 - DXS1227 - DXS98 - DXS52 - Xqter. The frequency of HPT was estimated to be 10 and the allele frequencies of the polymorphisms were obtained from the published genetic maps (GenBank). Varying the disease or allele frequencies had no effect on the results of the linkage analysis. Multipoint crossovers were analysed to determine the order of loci around HPT using a fixed framework of markers, as previously described. The likelihood for each position of HPT within the fixed framework of genetic markers was expressed as a location score, which was twice the natural logarithm of the odds ratio. The probability of the most likely locus order and the relative likelihood of other orders were then ascertained from this location score curve, as previously described.

**Results**

Eleven of the 12 polymorphic markers, whose order in Xq26-q27 has been established as Xcen - DXS1001 - DXS294 - DXS102 - F9 - DXS1232 - DXS984 - CDR1 - DXS105 - DXS1205 - DXS1227 - DXS98 - DXS52 - Xqter, proved informative in the two HPT families. An examination of the haplotypes within the 21 cM interval flanked centromerically by DXS1001 and telomERIC by DXS105 showed a haplotype (6, A, 2, B, 2, 4, D, E) that was shared by the two oldest carrier females (II.2 in family W/81 and III.2 in family P/60). This finding further supports the relatedness of the two families and is consistent with the results of our mitochondrial genome analysis that established a common ancestry for these two families from eastern Missouri. The data from the two families were therefore pooled for linkage analysis.

Linkage between HPT and eight of the 12 polymorphic loci (table 1) from Xq26-27 was established with the highest peak lod score of 7.06 at a recombination fraction (θ) = 0.05 (95% confidence interval = 0.001 to 0.15) being obtained between DXS984 and HPT. These results helped to confirm the previous localisation of HPT to this region, which was on the basis of linkage (lod score = 3.82) to only one marker, DXS98. Analysis of individual recombinants (fig 1) helped to define the region containing the HPT locus further. In family W/81, HPT is segregating in the eight affected or carrier subjects II.2, II.3, III.9, III.16, III.18, IV.4, IV.9, and V.2 with the haplotype (6, A, 2, B, 2, 4, D, E, 3, 1, g, 3) defined by the loci DXS1001, DXS294, DXS102, F9, DXS1232, DXS984, CDR1, DXS105, DXS1205, DXS1227, DXS98, and DXS52, respectively. However, in the remaining four affected or carrier subjects (III.13, IV.15, V.1, and V.3), recombinants are observed and these locate HPT in a 19 cM interval between F9 and
DXS52. A comparison of the haplotypes observed in the affected and carrier subjects between families W/81 and P/60, which have a common ancestry, shows a recombinant between HPT and the telomeric loci DXS1205, DXS1227, DXS98, and DXS52. The combined results from all of these recombinants in affected males and carrier females locate HPT in the 5 cM interval between F9 and DXS1205. The recombinant observed in the unaffected male IV.11 from family W/81 helps to narrow the limits of the region containing HPT further. IV.11 has the affected haplotype at the telomeric loci DXS984, CDR1, DXS1205, DXS1227, DXS98, and DXS52 but remains unaffected, thereby indicating a location for HPT that is centromeric to DXS984. Thus, the results of these recombinants indicate that HPT is located between F9 and DXS1205, a region of 5 cM, which can be narrowed further to a 2.5 cM interval by taking into account the recombinant observed in the unaffected subject IV.11. The likelihood of this location of HPT within the fixed order Xcen - DXS294 - DXS102 - F9 - DXS1232 - DXS984 - CDR1 - DXS105 - DXS1205 - DXS1227 - Xpter was quantitatively assessed using the LINKMAP program. Analysis using the LINKMAP program yielded the location score curve shown in fig. 2. There is a high peak telomeric to F9 and centromeric to DXS984, maximum location score=42.8, 1.1 cM telomeric to F9. This coincides with the location of DXS1232 which showed no recombination with HPT. There are seven subsidiary peaks with location scores ranging from 11.7 to 33.8 (table 2). An analysis of these indicates that the odds ratio favouring the order Xcen - DXS294 - DXS102 - F9 - (HPT, DXS1232) - DXS984 - CDR1 - DXS105 - DXS1205 - DXS1227 - Xpter versus a location of HPT unlinked to this cluster of nine loci is >1.3 x 10^7 (table 2). In addition, the odds ratio favouring other locations of HPT within this framework of nine loci is also significant. However, a location of HPT telomeric as opposed to centromeric to F9 is approximately 34,000 times more likely, and a location of HPT centromeric as opposed to telomeric to DXS984 is approximately 60 times more likely. These results indicate that HPT maps between F9 and DXS984, an interval that is estimated by genetic mapping to be 2.5 cM in size and by physical mapping to be 1.5 Mbp in size.

**Discussion**

Our location of the HPT gene to a 1.5 Mbp region between F9 and DXS984 considerably advances the search for this putative developmental gene. However, it is important to note that the location of HPT centromeric to DXS984 is only 60 times more likely than telomeric, and thus this interval may possibly be larger. The interval between F9 and DXS984 is contained within a YAC contig and three candidate genes, represented by SOX3, MCF.2, and the expressed sequence tag (EST) AS6, have been mapped to this region. SOX3 represents a member of the SRY family of developmental genes and MCF.2 is a member of the guanine nucleotide exchange factor for the RHO family of small GTP binding proteins. Investigation of these candidate genes for mutations in the HPT patients will help to elucidate their roles in the aetiology of this disorder of parathyroid gland development. However, such an analysis may require caution in interpretation as patients with deletions of this region have not been reported to suffer from hypocalcaemia or hypoparathyroidism. Such patients have been identified as they have deletions of F9 that extend into this region to include DXS984, and they suffer from haemophilia B (Christmas disease).

There may be at least three possible explanations for these contradicting observations from the deletion mapping studies in haemophilia B patients and our linkage mapping of HPT. Firstly, in the haemophilia B patient with a loss of this region, there may be a non-contiguous deletion with preservation of the HPT gene. However,}

**Table 1** Lod scores for linkage of markers from Xq26-q27 and hypoparathyroidism

<table>
<thead>
<tr>
<th>Locus</th>
<th>Peak</th>
<th>Lod scores Z(0)</th>
<th>Lod scores Z(0)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Z(0)</td>
<td>Z(0.001)</td>
<td>Z(0.01)</td>
</tr>
<tr>
<td>DXS1001</td>
<td>2.24</td>
<td>2.15</td>
<td>2.12</td>
</tr>
<tr>
<td>DXS294</td>
<td>3.40</td>
<td>3.24</td>
<td>3.02</td>
</tr>
<tr>
<td>DXS102</td>
<td>4.24</td>
<td>4.21</td>
<td>3.92</td>
</tr>
<tr>
<td>DXS1232</td>
<td>1.58</td>
<td>1.79</td>
<td>1.64</td>
</tr>
<tr>
<td>DXS984</td>
<td>7.06</td>
<td>6.58</td>
<td>5.95</td>
</tr>
<tr>
<td>CDR1</td>
<td>3.61</td>
<td>3.30</td>
<td>2.96</td>
</tr>
<tr>
<td>DXS105</td>
<td>6.23</td>
<td>5.79</td>
<td>5.20</td>
</tr>
<tr>
<td>DXS1205</td>
<td>4.58</td>
<td>4.48</td>
<td>4.30</td>
</tr>
<tr>
<td>DXS1227</td>
<td>4.03</td>
<td>3.40</td>
<td>2.88</td>
</tr>
<tr>
<td>DXS98*</td>
<td>3.40</td>
<td>2.88</td>
<td>2.39</td>
</tr>
<tr>
<td>DXS52*</td>
<td>2.49</td>
<td>1.79</td>
<td>1.64</td>
</tr>
</tbody>
</table>

*The previously published data for F9, DXS98, and DXS52 were pooled with the present data.

**Table 2** Order of genetic loci and their respective odds ratios as calculated from multipoint linkage analysis

<table>
<thead>
<tr>
<th>Locus order</th>
<th>Peak location score</th>
<th>Odds ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xcen-DXS294-HPT-DXS102-FIX-DXS1232-DXS984-CDR1-DXS105-DXS1205-DXS1227-Xpter</td>
<td>21.1</td>
<td>3.8 x 10^7</td>
</tr>
<tr>
<td>Xcen-DXS294-DXS102-HPT-FIX-DXS1232-DXS984-CDR1-DXS105-DXS1205-DXS1227-Xpter</td>
<td>18.9</td>
<td>1.3 x 10^7</td>
</tr>
<tr>
<td>Xcen-DXS294-DXS102-FIX-DXS1232-DXS984-CDR1-DXS105-DXS1205-DXS1227-Xpter</td>
<td>42.8</td>
<td>1.3 x 10^7</td>
</tr>
<tr>
<td>Xcen-DXS294-DXS102-FIX-DXS1232-DXS984-CDR1-DXS105-DXS1205-DXS1227-Xpter</td>
<td>33.8</td>
<td>2.2 x 10^7</td>
</tr>
<tr>
<td>Xcen-DXS294-DXS102-FIX-DXS1232-DXS984-CDR1-DXS105-HPT-DXS1205-DXS1227-Xpter</td>
<td>19.3</td>
<td>1.6 x 10^7</td>
</tr>
<tr>
<td>Xcen-DXS294-DXS102-FIX-DXS1232-DXS984-CDR1-DXS105-DXS1205-HPT-DXS1227-Xpter</td>
<td>11.7</td>
<td>3.5 x 10^7</td>
</tr>
</tbody>
</table>
Localisation of X-linked recessive hypoparathyroidism

We are grateful for support from the Medical Research Council (BHS, DHC, CS, UK, and PHD); grant No NH HGG000247 from the National Institutes of Health, USA (SM and DS); and grant No 15958 from The Shriners Hospital for Children, Chicago. SM is supported by a fellowship from the Shriners Hospital for Children, DT was an MRC Training Fellow, and PHD is an MRC PhD student.


29 Ron D, Tronick SR, Aronson SA, Eva A. Molecular cloning and characterization of the human db1 proto-oncogene: evidence that its overexpression is sufficient to transform NIH3T3 fibroblasts. EMBO J 1987;6:2465-73.


